Comparative Pharmacology
Head-to-head clinical analysis: AMOXAPINE versus ENDEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXAPINE versus ENDEP.
AMOXAPINE vs ENDEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
None Documented
None Documented
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Clinical Note
moderateAmoxapine + Budesonide
"The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone furoate
"The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate."
Clinical Note
moderateTerminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
Amoxapine + Desmopressin
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin."